Welcome to our dedicated page for Precigen SEC filings (Ticker: PGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Precigen, Inc. (PGEN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Precigen is a Nasdaq Global Select Market–listed biopharmaceutical company, and its filings offer detailed insight into the commercialization of PAPZIMEOS for recurrent respiratory papillomatosis (RRP), ongoing clinical programs, capital structure, and material agreements.
Current reports on Form 8-K document key corporate events, such as the announcement of financial results, entry into material definitive agreements, and capital transactions. For example, recent 8-K filings describe a senior secured term loan facility of up to $125 million with entities managed by Pharmakon Advisors, LP, a commercial supply agreement for PAPZIMEOS with an external manufacturing partner, and the conversion of Series A Convertible Perpetual Preferred Stock into common stock. Other 8-Ks cover shareholder meeting results, including approvals of equity incentive plan amendments and increases in authorized common shares.
Periodic reports such as annual and quarterly filings (Forms 10-K and 10-Q, when available) provide broader context on Precigen’s financial condition, risk factors, research and development activities, and commercialization efforts. These documents typically include discussions of PAPZIMEOS approval and launch, the company’s pipeline programs like PRGN-2009 and PRGN-3006, and the impact of financing arrangements and warrant liabilities on the balance sheet.
Investors can also review any Form 4 or related insider transaction filings, when present, to understand equity transactions by directors, officers, or significant shareholders. On Stock Titan, AI-powered tools summarize complex filings, highlight key terms in loan and supply agreements, and help explain the implications of capital structure changes, regulatory milestones, and other material events disclosed in Precigen’s SEC submissions.
Rutul R. Shah, Chief Operating Officer of Precigen, Inc. (PGEN), reported the vesting of 125,000 performance stock units on 09/12/2025. The filing shows these units are the second installment of PSUs originally granted on August 28, 2024 and vested upon achievement of the applicable performance condition for that installment. Each PSU is payable in one share of common stock or a cash equivalent. Following the reported transaction the filing lists 125,000 shares beneficially owned as a direct holding. The Form 4 is signed on behalf of Mr. Shah by an attorney-in-fact on 09/16/2025.
Nancy H. Agee, a director of Precigen, Inc. (PGEN), reported purchasing 15,000 shares of the company's common stock on 09/04/2025 at a price of $4.60 per share. After the purchase she beneficially owns 217,841 shares, held directly. The filing shows no derivative transactions and was signed on 09/05/2025 by Nancy H. Agee via attorney-in-fact.
Insider purchases reported by Precigen, Inc. director Nancy H. Agee. The Form 4 shows purchases of 15,360 shares at $3.20 on 08/19/2025 and 10,645 shares at $4.6492 on 08/28/2025, increasing her beneficial holdings from 192,196 to 202,841 shares following the latter transaction. The filing was signed on 08/29/2025 and was submitted by an attorney-in-fact.
Precigen, Inc. (PGEN) filed a Shelf Registration Statement on Form S-3 registering secondary sales by selling stockholders of up to 143,809,489 shares of Common Stock and 79,000 shares of Preferred Stock. The prospectus states all proceeds from these sales will go to the selling stockholders and the company will receive no proceeds. The registration covers a wide range of sale methods including block trades, at-the-market offerings, privately negotiated transactions, and hedging transactions.
The filing references incorporated reports and describes risks, noting purchasers may lose their entire investment. It identifies key officers and directors, and discloses concentrated beneficial ownership controlled by R.J. Kirk and affiliated entities. Legal and accounting fees related to the offering are included but cannot be estimated at this time.
Precigen, Inc. reported condensed financials for the quarter ended June 30, 2025 showing regulatory progress for its lead gene therapy and material financial strain. The FDA granted priority review to the Biologics License Application for PRGN-2012, with a PDUFA target action date of August 27, 2025; PRGN-2012 is intended to treat adults with recurrent respiratory papillomatosis and has not been approved.
Financially, the company recorded a net loss of $80,795 (amounts in thousands, i.e., $80.8 million) for the six months ended June 30, 2025 and used $35,302 of cash in operating activities in that period. As of June 30, 2025, it held $13,760 in cash and $45,993 in short-term investments (totaling $59,753). Warrant liabilities were $78,558 and Series A preferred mezzanine equity was $30,883, while accumulated deficit totaled $2,171,501. Management concluded these conditions raise substantial doubt about the company’s ability to continue as a going concern for one year absent additional funding or approval-related revenue.
Operationally, the company realigned to a single reporting segment and previously reduced its workforce by over 20% to focus resources on PRGN-2012. The company recorded a $3,907 goodwill impairment in Q2 2025 and recognized prior noncurrent asset impairments in 2024. These items, combined with large noncash warrant fair-value movements, contribute to earnings volatility despite regulatory momentum.
FAQ
What is the current stock price of Precigen (PGEN)?
What is the market cap of Precigen (PGEN)?
